Abecma for car-t
Ended Awarded Last action
- Contract number
- 36C24926F0096
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $378,650
Award facts
- Contract value 100% obligated
- $378,650.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lawrenceville, Lawrence Township, NJ 08648, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $39,717 |
About this award
Bristol-Myers Squibb Company received a delivery order modification worth $39,717.46 for ABECMA (idecabtagene vicleucel), a chimeric antigen receptor T cell therapy used to treat multiple myeloma and other hematologic malignancies. This delivery order, awarded on March 13, 2026, carries a total ceiling value of $378,650.30 and is scheduled for completion by September 12, 2026. The order was issued by Veterans Integrated Service Network 9 through Bristol-Myers Squibb's existing Federal Supply Schedule contract (FSS-61-IB: Pharmaceuticals and Drugs) with the Department of Veterans Affairs. The contract utilizes firm fixed-price terms with no set-aside designation and will be performed at Bristol-Myers Squibb's facility in Lawrenceville, New Jersey.
This delivery order represents one of more than fifty documented procurements issued to Bristol-Myers Squibb under its comprehensive FSS vehicle, which carries a $12.3 billion ceiling and extends through April 30, 2029. The Department of Veterans Affairs leverages this master schedule contract to provide eligible veterans access to advanced oncology and specialized cell therapies that represent current standards of care in cancer treatment. Bristol-Myers Squibb's substantial contract portfolio with the VA demonstrates the department's sustained reliance on the company's innovative pharmaceutical products, particularly CAR-T therapies and specialty oncology drugs, across multiple Veterans Integrated Service Networks to support the Veterans Health Administration's mission of delivering cutting-edge medical treatments.
Quick answers
Who was awarded contract 36C24926F0096?
36C24926F0096 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 9 (Veterans Health Administration) on March 13, 2026.
How much is contract 36C24926F0096 worth?
The government has obligated $378,650 on 36C24926F0096.
Is contract 36C24926F0096 an order under another contract?
Yes. 36C24926F0096 is a delivery order under 36F79724D0101, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24926F0096 competed?
The extent of competition for 36C24926F0096 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award